10x Genomics, Inc. (TXG) Stock Analysis
Healthcare · Health Information Services
Sell if holding. Engine safety override at $30.93: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 26%; Below-average business quality.
10x Genomics develops single-cell (Chromium) and spatial biology (Visium, Xenium) research instruments, consumables, and software for analyzing biological systems at cellular resolution, sold to academic, government, and biopharmaceutical researchers globally. Revenue was... Read more
Sell if holding. Engine safety override at $30.93: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 26%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.7/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — 10x Genomics, Inc.
Latest news
- NEWS 10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect - StockStory — StockStory positive
- NEWS Why 10x Genomics Stock Is Surging Today - TipRanks — TipRanks positive
- NEWS 10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance — Yahoo Finance positive
- NEWS 10x Genomics (TXG) Reports Q1 Loss, Beats Revenue Estimates - sharewise.com — sharewise.com positive
- NEWS 10x Genomics (TXG) Q1 2026 Earnings Transcript - The Globe and Mail — The Globe and Mail neutral
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductChromium solutions10-K Item 1A: 'Our dependency on revenue generated from the sale of our Chromium solutions'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Volatile — 7.7% daily ATR makes tight stops impractical. Position-size conservatively.static
Unprofitable operations — net margin -3.5%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $30.93: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 26%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $28.45. Score 4.7/10, moderate confidence.
Take-profit target: $34.94 (+14.2% upside). Prior stop was $28.45. Stop-loss: $28.45.
Concentration risk — Product: Chromium solutions; Target reached (-26.7% upside); Quality below floor (3.7 < 4.0).
10x Genomics, Inc. trades at a P/E of N/A (forward 145.9). TrendMatrix value score: 5.1/10. Verdict: Sell.
21 analysts cover TXG with a consensus score of 3.7/5. Average price target: $26.
What does 10x Genomics, Inc. do?10x Genomics develops single-cell (Chromium) and spatial biology (Visium, Xenium) research instruments, consumables,...
10x Genomics develops single-cell (Chromium) and spatial biology (Visium, Xenium) research instruments, consumables, and software for analyzing biological systems at cellular resolution, sold to academic, government, and biopharmaceutical researchers globally. Revenue was $642.8M in 2025 with 8,046 cumulative instruments sold; no single customer exceeded 10% of business.